A Phase I/II Safety, Pharmacokinetic, and Pharmacodynamic Study of APS001F With Flucytosine and Maltose for the Treatment of Advanced and/or Metastatic Solid Tumors

Trial Profile

A Phase I/II Safety, Pharmacokinetic, and Pharmacodynamic Study of APS001F With Flucytosine and Maltose for the Treatment of Advanced and/or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs APS 001F (Primary) ; Flucytosine; Maltose
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Anaeropharma Science
  • Most Recent Events

    • 16 Feb 2017 Planned End Date changed from 1 Aug 2016 to 1 Aug 2018.
    • 16 Feb 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2018.
    • 29 Dec 2014 Planned End Date changed from 1 Sep 2015 to 1 Aug 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top